Another weak quarter prompts much-needed (guidance) adjustments

30/10/25 -"Q3 was weak, with glaring pricing challenges across the board. Even though there were some notable volume gains, the top line remained under pressure. Unavoidably, there were guidance adjustments. ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

30/10/25

Download

You may also be interested by these reports :

30/10/25

Eramet

Q3 was weak, with glaring pricing challenges across the board. Even though there were some notable volume gains, the top line remained under ...

30/10/25

Outokumpu

Our target price goes down after our earnings revision, prompting a change in recommendation from Add to Reduce. It is probably all about timing. ...

30/10/25

Tenaris

Tenaris reported expected results, maintaining high margins and strong cash generation, even in a challenging oil price environment. However, Q4 is ...

30/10/25

AMAG

Weak 3Q25 – But EBITDA 2025E guidance specified to the upper end of range

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue